Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-02-28

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non alcoholic fatty liver diseases (NAFLD) are represented by two main pathological conditions, hepatic steatosis (HS) and non alcoholic steatohepatitis (NASH), which are characterized by the accumulation of fat in the liver. The diagnosis of these two entities is achieved by histology and neither imaging nor biochemical markers are accurate enough to discriminate them. At the contrary of HS, NASH features hepatocyte necrosis, inflammation and fibrosis of variable intensity that could progress and ultimately evolve to cirrhosis. Therefore, it is important to distinguish between HS and NASH in order to treat the patients accordingly. In this study, the investigators aim to understand the molecular mechanisms that govern the transition from benign steatosis to complicated NASH. The investigators will analyze by "Q-RT-PCR" and "DNA microarray" technologies in the liver of obese patients, the expression of genes that are susceptible to be involved in the pathogenesis of NAFLD and identify the potential signaling pathways responsible for the progression of the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fatty Liver and Ectopic Fat in Overweight and Obese Patients

NCT00886301

Steatohepatitis

COMPLETED NA

Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients

NCT04493814

NAFLD Type 2 Diabetes

UNKNOWN

Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients

NCT01695083

Morbid Obesity Non Alcoholic Steatohepatitis

COMPLETED

Fibrosis Reduction in Non Alcoholic Steatohepatitis

NCT05798702

NASH With Fibrosis Weight Loss Bariatric Surgery Candidate

ACTIVE_NOT_RECRUITING NA

Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

NCT05507151

Nonalcoholic Fatty Liver Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T

(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.

cholecystectomy or benign liver tumor removal

Intervention Type PROCEDURE

cholecystectomy or benign liver tumor removal

A

(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).

Bariatric surgery

Intervention Type PROCEDURE

Gastric bypass.

B

(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).

Bariatric surgery

Intervention Type PROCEDURE

Gastric bypass.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bariatric surgery

Gastric bypass.

Intervention Type PROCEDURE

cholecystectomy or benign liver tumor removal

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group T(n=30): patient without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor
* Group A (n=30): patient with central adiposity, insulin resistance and hepatic steatosis (histology).
* Group B (n=30): patient with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).

Exclusion Criteria

* viral or autoimmune hepatitis
* hematochromatosis
* alcohol consumption (\> 20 g/24h women, \>30 g/24h men)
* type 1 diabetes
* inflammation or infection before procedure
* abnormal hemostasis or coagulation- pregnancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No